The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
Titel:
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
Auteur:
Gibson, C. Michael Kerneis, Mathieu Yee, Megan K. Daaboul, Yazan Korjian, Serge Mehr, Ali Poyan Tricoci, Pierluigi Alexander, John H. Kastelein, John J.P. Mehran, Roxana Bode, Christoph Lewis, Basil S. Mehta, Ravindra Duffy, Danielle Feaster, John Halabi, Majdi Angiolillo, Dominick J. Duerschmied, Daniel Ophuis, Ton Oude Merkely, Bela